Article
Ibrutinib versus bendamustine plus rituximab for first-line treatment of 65 or older patients with untreated chronic lymphocytic leukemia without del(17p)/TP53 mutation in China: a lifetime economic research study.
BMC health services research - 5 Dec 2023
Hong Yuan, Chen Xichuang, Hong Yuanquan, Xiao Xingfang, Wang Yan, You Xiaohong, Mi Jingyi, Zhou Tao, Zheng Panpan, Huang Zhihu
Abstract excerpt
BACKGROUND: The incidence and mortality rates of patients with chronic lymphocytic leukemia (CLL) in China have recently increased. This study performed a long-term economic evaluation of the first-line treatment strategies ibrutinib (IB) or bendamustine (BE) plus rituximab (RI) for previously untreated older patients with CLL without the del(17p)/TP53 mutation in China. METHODS: Based on clinical data from...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.